These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9403288)

  • 1. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
    Kleist P; Ehrlich A; Suzuki Y; Timmer W; Wetzelsberger N; Lücker PW; Fuder H
    Eur J Clin Pharmacol; 1997; 53(2):149-52. PubMed ID: 9403288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.
    Fuder H; Kleist P; Birkel M; Ehrlich A; Emeklibas S; Maslak W; Stridde E; Wetzelsberger N; Wieckhorst G; Lücker PW
    Eur J Clin Pharmacol; 1997; 53(2):153-7. PubMed ID: 9403289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
    Kim HS; Oh M; Kim EJ; Song GS; Ghim JL; Shon JH; Kim DH; Shin JG
    Int J Clin Pharmacol Ther; 2014 Nov; 52(11):1005-11. PubMed ID: 25161160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of acarbose and voglibose in healthy subjects.
    Kageyama S; Nakamichi N; Sekino H; Nakano S
    Clin Ther; 1997; 19(4):720-9. PubMed ID: 9377616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Food Thickeners on the Inhibitory Effect of Voglibose Oral-disintegrating Tablets on Post-prandial Elevation of Blood Sugar Levels.
    Tomita T; Goto H; Sumiya K; Yoshida T; Tanaka K; Kohda Y
    Yakugaku Zasshi; 2016; 136(8):1171-6. PubMed ID: 27477734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.
    Göke B; Fuder H; Wieckhorst G; Theiss U; Stridde E; Littke T; Kleist P; Arnold R; Lücker PW
    Digestion; 1995; 56(6):493-501. PubMed ID: 8536820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
    Kawagishi T; Nishizawa Y; Taniwaki H; Tanaka S; Okuno Y; Inaba M; Ishimura E; Emoto M; Morii H
    Diabetes Care; 1997 Oct; 20(10):1529-32. PubMed ID: 9314629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of two oral formulations of glyburide (glibenclamide).
    Flores-Murrieta FJ; Carrasco-Portugal Mdel C; Reyes-García G; Medina-Santillán R; Herrera JE
    Proc West Pharmacol Soc; 2007; 50():64-6. PubMed ID: 18605232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
    Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K;
    Lancet; 2009 May; 373(9675):1607-14. PubMed ID: 19395079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of voglibose administered alone, administered with metformin, and administered with metformin in a fixed-dose combination in healthy Korean subjects
.
    Kim HS; Oh M; Kim EJ; Song GS; Kim EY; Shin JG
    Int J Clin Pharmacol Ther; 2018 Nov; 56(11):544-550. PubMed ID: 30178742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validated high-performance liquid chromatographic method for the determination of glibenclamide in human plasma and its application to pharmacokinetic studies.
    Niopas I; Daftsios AC
    J Pharm Biomed Anal; 2002 May; 28(3-4):653-7. PubMed ID: 12008145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.
    Choi HK; Oh M; Kim EJ; Song GS; Ghim JL; Shon JH; Kim HS; Shin JG
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):147-53. PubMed ID: 25546164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
    Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
    Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.